Swiss National Bank
NBIX icon

Swiss National Bank’s Neurocrine Biosciences NBIX Stock Holding History

Swiss National Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.5M Buy
292,600
+20,800
+8% +$2.76M 0.02% 505
2025
Q4 		$38.5M Sell
271,800
-13,500
-5% -$1.96M 0.02% 493
2025
Q3 		$40.1M Sell
285,300
-14,100
-5% -$1.91M 0.02% 493
2025
Q2 		$37.6M Buy
299,400
+13,900
+5% +$1.59M 0.02% 493
2025
Q1 		$31.6M Buy
285,500
+200
+0.1% +$25.3K 0.02% 514
2024
Q4 		$38.9M Sell
285,300
-13,400
-4% -$1.66M 0.03% 486
2024
Q3 		$34.4M Buy
298,700
+4,100
+1% +$562K 0.02% 522
2024
Q2 		$40.6M Buy
294,600
+400
+0.1% +$54.9K 0.03% 467
2024
Q1 		$40.6M Sell
294,200
-11,100
-4% -$1.52M 0.03% 478
2023
Q4 		$40.2M Sell
305,300
-8,500
-3% -$978K 0.03% 481
2023
Q3 		$35.3M Sell
313,800
-38,400
-11% -$4.04M 0.03% 499
2023
Q2 		$33.2M Sell
352,200
-28,300
-7% -$2.77M 0.02% 551
2023
Q1 		$38.5M Sell
380,500
-8,200
-2% -$853K 0.03% 524
2022
Q4 		$46.4M Sell
388,700
-25,527
-6% -$2.99M 0.03% 463
2022
Q3 		$44M Buy
414,227
+1,300
+0.3% +$132K 0.03% 486
2022
Q2 		$40.3M Buy
412,927
+2,100
+0.5% +$194K 0.03% 517
2022
Q1 		$38.5M Buy
410,827
+51,200
+14% +$4.34M 0.02% 554
2021
Q4 		$30.6M Sell
359,627
-13,300
-4% -$1.22M 0.02% 595
2021
Q3 		$35.8M Sell
372,927
-10,100
-3% -$954K 0.02% 567
2021
Q2 		$37.3M Buy
383,027
+42,327
+12% +$4.06M 0.02% 581
2021
Q1 		$33.1M Buy
340,700
+6,100
+2% +$640K 0.02% 579
2020
Q4 		$32.1M Sell
334,600
-8,800
-3% -$850K 0.02% 562
2020
Q3 		$33M Sell
343,400
-3,400
-1% -$393K 0.03% 516
2020
Q2 		$42.3M Buy
346,800
+7,300
+2% +$807K 0.04% 448
2020
Q1 		$29.4M Buy
339,500
+65,200
+24% +$6.38M 0.03% 469
2019
Q4 		$29.5M Buy
274,300
+102,500
+60% +$10.7M 0.03% 523
2019
Q3 		$15.5M Buy
171,800
+2,900
+2% +$271K 0.02% 633
2019
Q2 		$14.3M Buy
168,900
+3,700
+2% +$304K 0.02% 662
2019
Q1 		$14.6M Buy
165,200
+4,200
+3% +$351K 0.02% 634
2018
Q4 		$11.5M Buy
161,000
+4,500
+3% +$431K 0.01% 635
2018
Q3 		$19.2M Hold
156,500
– – 0.02% 586
2018
Q2 		$15.4M Buy
156,500
+2,800
+2% +$251K 0.02% 617
2018
Q1 		$12.7M Buy
153,700
+3,500
+2% +$296K 0.02% 644
2017
Q4 		$11.7M Buy
150,200
+2,900
+2% +$198K 0.01% 672
2017
Q3 		$9.03M Buy
147,300
+1,900
+1% +$100K 0.01% 727
2017
Q2 		$6.69M Buy
145,400
+1,800
+1% +$87.3K 0.01% 833
2017
Q1 		$6.22M Buy
143,600
+1,000
+0.7% +$42.8K 0.01% 859
2016
Q4 		$5.52M Buy
142,600
+2,400
+2% +$109K 0.01% 896
2016
Q3 		$7.1M Sell
140,200
-1,800
-1% -$89.6K 0.01% 741
2016
Q2 		$6.45M Hold
142,000
– – 0.01% 786
2016
Q1 		$5.42M Buy
142,000
+28,800
+25% +$1.14M 0.01% 838
2015
Q4 		$6.4M Buy
113,200
+600
+0.5% +$30.5K 0.02% 697
2015
Q3 		$4.48M Buy
112,600
+15,500
+16% +$749K 0.01% 839
2015
Q2 		$4.64M Buy
97,100
+5,200
+6% +$220K 0.01% 809
2015
Q1 		$3.65M Buy
91,900
+7,900
+9% +$283K 0.01% 939
2014
Q4 		$1.88M Buy
84,000
+2,000
+2% +$37.9K 0.01% 1304
2014
Q3 		$1.28M Sell
82,000
-1,900
-2% -$28.4K ﹤0.01% 1510
2014
Q2 		$1.25M Hold
83,900
– – ﹤0.01% 1584
2014
Q1 		$1.35M Buy
83,900
+24,500
+41% +$419K 0.01% 1498
2013
Q4 		$555K Hold
59,400
– – ﹤0.01% 1919
2013
Q3 		$672K Sell
59,400
-3,000
-5% -$41.2K ﹤0.01% 1736
2013
Q2 		$835K Buy
+62,400
New +$767K ﹤0.01% 1546

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's NBIX Position: Q1 2026 in Review

Swiss National Bank increased its Neurocrine Biosciences (NBIX) stake by 7.7% in Q1 2026, buying an estimated $2.76M and bringing the position to 292,600 shares worth $38.5M. The position accounts for 0.02% of the portfolio, ranked #505.

Swiss National Bank first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $46.4M in Q4 2022. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Swiss National Bank held 292,600 shares of Neurocrine Biosciences worth $38.5M as of Q1 2026.
  • Swiss National Bank bought 20,800 Neurocrine Biosciences shares in Q1 2026, an estimated $2.76M.
  • Neurocrine Biosciences made up 0.02% of Swiss National Bank's portfolio in Q1 2026, its #505 holding.
  • Swiss National Bank first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Swiss National Bank's Neurocrine Biosciences position peaked at $46.4M in Q4 2022.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.